Arcera Life Sciences signs strategic MoU with Fosun Pharma to advance global biotech innovation in Abu Dhabi

UAE — Arcera Life Sciences, a global life sciences company headquartered in Abu Dhabi, and Shanghai Fosun Pharmaceutical Group Co., Ltd. have signed a Memorandum of Understanding to establish a long-term strategic collaboration covering licensing, technology development, neuroscience innovation, and broader value creation across the global life sciences sector.

The agreement was signed by Sunil Bhilotra, Chief Investment Officer of Arcera, and Xingli Wang, Co-President of Fosun Pharma and CEO of its Innovative Medicines Division in Shanghai, China, in a formal ceremony attended by senior executives from both organizations.

Leadership presence and representation

Among those present were Qunbin Wang, Co-Chairman of Fosun International; Yuqing Chen, Chairman of Fosun Pharma; Isabel Afonso, Chief Executive Officer of Arcera; and Rafael Ferrer, Senior Vice President for Corporate Development at Arcera.

The partnership aligns with the Comprehensive Strategic Partnership between China and the United Arab Emirates, as well as Abu Dhabi’s Healthcare Life Sciences Vision 2030, which aims to strengthen the emirate’s position as a global healthcare hub.

In addition, the collaboration seeks to enhance innovation pathways and improve cross-border market access, thereby accelerating the delivery of advanced therapies to patients in the Middle East and other international markets.

Core areas of collaboration

Under the MoU, the two companies will focus on three main pillars, beginning with regional and global licensing of pharmaceutical assets across oncology, neuroscience, rare diseases, and cardiometabolic conditions.

This includes evaluating compounds in advanced clinical development or commercial stages in China for potential expansion into new markets.

Secondly, the partners will explore frontier technology incubation through potential joint ventures or new entities aimed at localizing advanced biotechnology capabilities in the United Arab Emirates.

These efforts will span small molecules, biologics, radiopharmaceuticals, small interfering RNA therapies, and cell and gene therapies, supporting sovereign research and development capacity in the region.

Thirdly, the collaboration will prioritize neuroscience, with a particular focus on neurodegenerative diseases such as Alzheimer’s disease, where significant unmet medical needs continue to exist globally.

Executive perspectives

Arcera Chief Executive Officer Isabel Afonso said the partnership represents another milestone in building a global life sciences ecosystem anchored in Abu Dhabi.

Combining Fosun Pharma’s drug development expertise with Arcera’s commercial and manufacturing capabilities will create a model for China–UAE collaboration that accelerates innovation and patient access.

She added that this agreement also positions Abu Dhabi as a strategic bridge linking Asian biotechnology innovation with global healthcare markets.

Fosun Pharma Co-President Xingli Wang said the MoU marks a significant step in the company’s international expansion strategy and its commitment to deeper global partnerships.

He noted that Arcera brings strong industry capabilities, while Fosun Pharma contributes more than three decades of experience in research, development, and manufacturing at scale.

He emphasized both organizations will work closely to leverage complementary strengths to accelerate development and delivery of innovative therapies across the Middle East and beyond.